Dinesh Ph Patel Sells 24,890 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Dinesh Ph Patel sold 24,890 shares of the firm’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $84.03, for a total value of $2,091,506.70. Following the sale, the chief executive officer owned 574,505 shares of the company’s stock, valued at $48,275,655.15. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Protagonist Therapeutics Stock Down 1.6%

Shares of PTGX opened at $81.76 on Thursday. The business’s 50 day moving average is $86.42 and its two-hundred day moving average is $72.48. The firm has a market cap of $5.11 billion, a price-to-earnings ratio of 131.87 and a beta of 2.26. Protagonist Therapeutics, Inc. has a 52-week low of $33.70 and a 52-week high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The company had revenue of $4.71 million for the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. On average, equities analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its stake in shares of Protagonist Therapeutics by 11.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock worth $91,000 after acquiring an additional 146 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares during the last quarter. Parkman Healthcare Partners LLC lifted its holdings in Protagonist Therapeutics by 0.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock worth $4,109,000 after purchasing an additional 253 shares during the last quarter. Guggenheim Capital LLC lifted its stake in shares of Protagonist Therapeutics by 1.6% in the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock worth $1,062,000 after buying an additional 303 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Protagonist Therapeutics by 138.9% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after acquiring an additional 314 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Key Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Analyst support remains strong: several brokerages have raised price targets or reiterated buy/overweight ratings (Johnson Rice $112, Citizens Jmp $102, JPMorgan raised to overweight). That analyst momentum and a consensus “Moderate Buy” rating help cushion downside. Read More.
• Neutral Sentiment: Company fundamentals and outlook remain mixed — recent quarterly results missed revenue and EPS expectations, but PTGX is a clinical‑stage biotech with late‑stage programs (PTG‑100) that could re‑rate the stock on positive clinical/data news. No new clinical readouts were announced today. Read More.
• Negative Sentiment: Large, clustered insider sales — CEO Dinesh Patel sold multiple tranches (including 4,068 shares on Jan. 27 and larger sales earlier this week), CFO Asif Ali sold 46,203 shares (reducing his stake ~43%), and director/insider Arturo Molina sold >18k shares across days. These sizeable officer-level sales are being viewed negatively and likely pressured the stock today. Read More.
• Negative Sentiment: The CFO’s SEC filing shows the large Jan. 27 sale (46,203 shares) and is particularly notable because a near‑half reduction by a finance officer can raise investor concern about insider conviction. Read More.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on PTGX shares. JPMorgan Chase & Co. increased their price objective on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Citigroup increased their price target on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Barclays increased their price objective on shares of Protagonist Therapeutics from $88.00 to $108.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Wedbush raised their target price on Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a research note on Tuesday, October 28th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.77.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.